Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,069 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo, Cohort 3 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of PRA023 in Healthy Volunteers

NCT04676178
View directory record Official record
Conditions
Healthy
Interventions
PRA023, Placebo
Drug · Other
Lead sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants

NCT05726851
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2025, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 14, 2026, 7:13 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

NCT02170012
View directory record Official record
Conditions
Healthy Elderly
Interventions
PF-06743649, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 14, 2026, 7:13 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NCT05503264
View directory record Official record
Conditions
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Interventions
Satralizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
11
States / cities
Birmingham, Alabama • Newport Beach, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-68179280 in Healthy Participants

NCT04844463
View directory record Official record
Conditions
Healthy
Interventions
JNJ-68179280, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers

NCT01893528
View directory record Official record
Conditions
Healthy Volunteers
Interventions
REGN2009, placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 14, 2026, 7:13 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease

NCT07839871
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
5 Years to 17 Years
Enrollment
920 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
South Euclid, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional

Intravenous Zotatifin in Adults With Mild or Moderate COVID-19

NCT04632381
View directory record Official record
Conditions
Corona Virus Infection
Interventions
Zotatifin, Placebo
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Anniston, Alabama • Cullman, Alabama • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Not applicable Interventional Results available

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African Americans Study (GENE-FORECAST): Sodium Intervention Trial (SIT)

NCT04717336
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Sodium Chloride, Placebo
Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional

Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease

NCT02386306
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
GC021109, Placebo
Drug · Other
Lead sponsor
GliaCure, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
5
States / cities
Long Beach, California • Deerfield Beach, Florida • Hallandale, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 14, 2026, 7:13 PM EDT
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
342
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 262 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers

NCT02833389
View directory record Official record
Conditions
Neuropathic Diabetic Foot Ulcers
Interventions
Placebo, UTTR1147A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Mesa, Arizona • San Francisco, California • Durango, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 2 Interventional

Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis

NCT01294410
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Anti-IP-10 Antibody
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
La Jolla, California • Santa Monica, California • Wheat Ridge, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 14, 2026, 7:13 PM EDT
Recruiting Phase 1 Interventional

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

NCT07305818
View directory record Official record
Conditions
Graves Disease
Interventions
MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD
Biological
Lead sponsor
Merida Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Torrance, California • Hollywood, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants

NCT05927597
View directory record Official record
Conditions
Healthy Volunteers
Interventions
INS1007, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 50 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 14, 2026, 7:13 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults

NCT05978908
View directory record Official record
Conditions
Safety Issues, Tolerance
Interventions
FC-12738, Saline
Drug
Lead sponsor
Neurodegenerative Disease Research Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of DCR-AUD in Healthy Volunteers

NCT05021640
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
DCR-AUD, Placebo for DCR-AUD
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea

NCT01060748
View directory record Official record
Conditions
Diarrhea
Interventions
ACE527, Placebo
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT04629170
View directory record Official record
Conditions
Healthy, Enteric Hyperoxaluria
Interventions
SYNB8802, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 74 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Tucson, Arizona • Tampa, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

NCT03400488
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AZD5718 oral suspension, Placebo matching AZD5817 oral suspension
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study of LY2886721 Single Doses in Healthy Subjects

NCT01133405
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2886721, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 14, 2026, 7:13 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3463251 in Healthy Participants

NCT03764774
View directory record Official record
Conditions
Healthy
Interventions
LY3463251, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 2 Interventional

Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty

NCT05283486
View directory record Official record
Conditions
Sarcopenia, Frailty, Aging
Interventions
MYMD-1 600MG, MYMD-1 750mg, MYMD-1 900mg, MYMD-1 1050mg, placebo 600mg, placebo 750mg, placebo 900mg, placebo 1050mg
Drug
Lead sponsor
TNF Pharmaceuticals, Inc.
Industry
Eligibility
65 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Clearwater, Florida • Tampa, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 14, 2026, 7:13 PM EDT